American Journal of Physiology-Endocrinology and Metabolism · 1988 · 33 citations · 23 references
Life SciencesEndocrinologyPharmacologyCell SignalingGene ExpressionSignal TransductionEndocrine PharmacologyHormone SignalingReceptor RegulationSteroid Hormone SignalingSteroid PharmacologyCyclic Adenosine Monophosphate PathwayCyclic Adenosine Monophosphate SignalingGlucocorticoid PharmacologyGlucocorticoid Receptor SignalingGlucocorticoid ReceptorsGlucocorticoid SignalingReceptor-mediated InteractionsSteroidogenic Enzyme Regulation
Experiments were undertaken using isolated rat liver cells to determine whether the stimulation of angiotensinogen synthesis by glucocorticoids, estrogens, and angiotensin II is due to a direct action on the liver and whether these effects involve an increase in angiotensinogen mRNA levels. Dexamethasone and other corticosteroids stimulated angiotensinogen mRNA accumulation in hepatocytes up to 3.5-fold after 2.5-3 h of incubation. The effect of dexamethasone was inhibited competitively by the glucocorticoid antagonist RU486. These results indicate that the stimulation of hepatic angiotensinogen production by glucocorticoids is a direct, receptor-mediated effect and occurs via an increase in angiotensinogen mRNA accumulation. The stimulatory diastereomer of adenosine 3',5'-cyclic phosphorothioate, an active adenosine 3',5'-cyclic monophosphate analogue, caused a 1.8-fold increase in angiotensinogen mRNA accumulation, and this effect was additive with that of dexamethasone, suggesting a distinct mechanism of action. Angiotensin II increased angiotensinogen mRNA levels by only 1.2-fold after 2.5 h, whereas ethinyl estradiol had no effect.
23
George M. Church, W Gilbert · Proceedings of the National Academy of Sciences · 1984 · 8.2K citations · Full text